ADVA
1.4.2020 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the European Advanced Networking Test Center (EANTC) has validated the interoperability of its unique carrier-grade network operating system (NOS) with routers and network management systems from a wide range of vendors. ADVA’s Ensemble Activator successfully demonstrated interoperability in a series of tests showing how disaggregated packet devices can significantly enhance the scale and functionality of networks. The software-based NOS, which turns bare-metal switches into powerful packet network devices, proved fully compatible with third-party switching and routing devices while supporting segment routing and MPLS Layer 3 services. What’s more, it showed ease of integration into third-party management systems through open interfaces for telemetry streaming and SDN control. Conducted at the EANTC’s facility in Berlin, the tests highlight the value of openness and show how Ensemble Activator can complement legacy packet networks with disaggregated packet devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200401005039/en/
“Putting our Ensemble Activator through EANTC’s rigorous tests emphasizes the commitment to openness and interoperability that underpins all ADVA innovation. But we’re also showing the industry how we can bring something special to Layer 3. Our years of experience with lower layer solutions give us a unique understanding of the operational aspects of networks,” said Eli Angel, VP, product line management, ADVA. “Our Ensemble Activator is proven to enable high-value disaggregated cell site gateway solutions, bringing the agility of software-based feature development to mobile networks. Now, we’re going even further and extending our unique MEF 3.0-certified solution with higher layer networking capabilities. These tests highlight how our Ensemble Activator supports segment routing and MPLS. What more, our disaggregated packet solution releases communication service providers from vendor lock-in and delivers total agility.”
Engineered specifically for white box switching, ADVA’s Ensemble Activator is the result of years of experience in deploying optical, Carrier Ethernet and IP/MPLS networks. The NOS is designed for zero-touch provisioning using the Open Networking Install Environment (ONIE) framework. Its success in the latest round of EANTC tests demonstrates how Ensemble Activator’s open management and control interfaces support easy integration into multi-vendor networks. ADVA’s strategy of extending its software capabilities from Layer 2 to higher layer functions offers the market a fresh approach to deploying flexible, feature-rich software-based MPLS routing and segment routing solutions in an open environment. ADVA’s long experience of building disaggregated telecommunication infrastructure will bring a host of benefits to operators and users of virtual private networks.
“Our evaluation confirms that Ensemble Activator successfully interworked with third-party routers and network management systems. In environments featuring technology from other major vendors, ADVA’s disaggregated software NOS was verified in tests focused on Layer 2 and Layer 3 VPNs, segment routing, and control and data plane capabilities,” commented Carsten Rossenhövel, managing director, EANTC. “This latest interoperability event was a major success with more than 100 attendees from 16 vendors, including many participating remotely. Its program reflected a shift across the industry to software-defined networking with many testing scenarios involving programmability and manageability. ADVA’s Ensemble Activator easily integrated and successfully interoperated in several of these tests, such as those focused on vendor-neutral Layer 3 segment routing and telemetry streaming.”
Further information on the interoperability testing is available on the EANTC website: https://adva.li/eantc-2020 .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About EANTC
EANTC (European Advanced Networking Test Center) is internationally recognized as one of the world's leading independent test centers for telecommunication technologies. Based in Berlin, Germany, the company offers vendor-neutral consultancy and realistic, reproducible high-quality testing services since 1991. Customers include leading network equipment manufacturers, tier-1 service providers, large enterprises and governments worldwide. EANTC's proof of concept, acceptance tests and network audits cover established and next-generation fixed and mobile network technologies. www.eantc.de
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005039/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom